Mantle cell lymphoma (MCL) is a rare form of B-cell non-Hodgkin’s lymphoma (NHL), accounting for 3-6% of new NHL cases. The term MCL derives from the growth pattern of the lymphoma, with tumor cells originating in the mantle zone of the lymph node. The clinical behavior of MCL is usually aggressive, and the clinical presentation frequently includes extranodal involvement of the bone marrow and gut. The disease often initially responds to treatment, but disease relapse inevitably occurs within 1-2 years. The prognosis of patients with MCL is the poorest among B-cell lymphoma patients, with median overall survival of 5-7 years.
Recent events and opinion
Recent events and opinion
- Costly therapies will drive the growth of the mantle cell lymphoma market during 2016-25, despite multiple generic/biosimilar entries.
- Imbruvica has achieved the highest response rates among the new targeted approaches in refractory or early relapse cases, leading to its usage in previously treated patients.
- Incident cases of the three major subtypes of NHL will increase by at least a quarter over the forecast period.
- Rituxan-based therapies remain the standard of care for the treatment of mantle cell lymphoma.
- CD antigens are the main targets in the pipeline for mantle cell lymphoma.
Table of Contents
Table of Contents (Forecast, Treatment and Epidemiology Datapacks included)FORECAST: MANTLE CELL LYMPHOMA (Published on 15 April 2016)
OVERVIEW
EXECUTIVE SUMMARY
MARKET OVERVIEW AND TRENDS
MARKET DEFINITION AND METHODOLOGY
IMBRUVICA (IBRUTINIB)
REVLIMID (LENALIDOMIDE)
RITUXAN (RITUXIMAB)
TORISEL (TEMSIROLIMUS)
VELCADE (BORTEZOMIB)
PRIMARY RESEARCH METHODOLOGY
TREATMENT: MANTLE CELL LYMPHOMA (Published on 14 April 2016)
OVERVIEW
EXECUTIVE SUMMARY
PRIMARY RESEARCH METHODOLOGY
DISEASE DEFINITION AND DIAGNOSIS
PATIENT SEGMENTATION
COUNTRY TREATMENT TREES
CURRENT TREATMENT OPTIONS
PRESCRIBING TRENDS: LOCALIZED STAGE (I/II)
PRESCRIBING TRENDS: BULKY STAGE (II/III/IV)
EPIDEMIOLOGY: MANTLE CELL LYMPHOMA (Published on 11 April 2018)
EXECUTIVE SUMMARY
PRODUCT OVERVIEW
PRODUCT PROFILE: IMBRUVICA
PRODUCT PROFILE: REVLIMID
PRODUCT PROFILE: RITUXAN
PRODUCT PROFILE: TORISEL
PRODUCT PROFILE: TREANDA
PRODUCT PROFILE: VELCADE
PIPELINE: MANTLE CELL LYMPHOMA (Published on 29 February 2016)
OVERVIEW
EXECUTIVE SUMMARY
CLINICAL PIPELINE OVERVIEW
PRODUCT PROFILE (LATE STAGE): DARZALEX
PRODUCT PROFILE (LATE STAGE): GAZYVA
PRODUCT PROFILE (LATE STAGE): KTE-C19
PRODUCT PROFILE (LATE STAGE): KYPROLIS
List of Figures
Figure 1: Mantle cell lymphoma market value across the US, Japan, and five major EU markets, by country, 2016-25
Figure 2: Mantle cell lymphoma market value in the US, Japan, and five major EU markets, by drug status, 2016-25
Figure 3: Mantle cell lymphoma drug sales in the US, Japan, and five major EU markets, by drug, 2016-25
Figure 4: Patient-based forecast methodology for mantle cell lymphoma
Figure 5: Price sources and calculations, by country
Figure 6: Imbruvica sales for mantle cell lymphoma across the US and five major EU markets, by country, 2016-25
Figure 7: Revlimid sales for mantle cell lymphoma across the US, Japan, and five major EU markets, by country, 2016-25
Figure 8: Rituxan sales for mantle cell lymphoma across the US, Japan, and five major EU markets, by country, 2016-25
Figure 9: Torisel sales for mantle cell lymphoma across the five major EU markets, by country, 2016-25
Figure 10: Velcade sales for mantle cell lymphoma across the US, Japan, and five major EU markets, by country, 2016-25
Figure 11: Proportion of mantle cell lymphoma patients at localized or advanced stage of disease at diagnosis, by country, 2016
Figure 12: Proportion of localized stage mantle cell lymphoma patients receiving each treatment type, by country, 2016
Figure 13: Proportion of localized stage mantle cell lymphoma patients receiving each line of anti-cancer therapy, by country, 2016
Figure 14: Proportion of localized stage mantle cell lymphoma patients receiving each type of first-line/induction therapy, by country, 2016
Figure 15: Proportion of localized stage mantle cell lymphoma patients receiving each aggressive first-line/induction therapy, by country, 2016
Figure 16: Proportion of localized stage mantle cell lymphoma patients receiving each less aggressive first-line/induction therapy, by country, 2016
Figure 17: Proportion of localized stage mantle cell lymphoma patients receiving each first-line maintenance therapy, by country, 2016
Figure 18: Proportion of mantle cell lymphoma patients (irrespective of stage) receiving each second-line therapy, by country, 2016
Figure 19: Proportion of mantle cell lymphoma patients (irrespective of stage) receiving each second-line maintenance therapy, by country, 2016
Figure 20: Proportion of mantle cell lymphoma patients (irrespective of stage) receiving third-line therapy, by country, 2016
Figure 21: Proportion of mantle cell lymphoma patients (irrespective of stage) receiving each third-line maintenance therapy, by country, 2016
Figure 22: Proportion of bulky stage mantle cell lymphoma patients receiving each treatment type, by country, 2016
Figure 23: Proportion of bulky stage mantle cell lymphoma patients receiving each line of anti-cancer therapy, by country, 2016
Figure 24: Proportion of bulky stage mantle cell lymphoma patients receiving each type of first-line/induction therapy, by country, 2016
Figure 25: Proportion of bulky stage mantle cell lymphoma patients receiving aggressive first-line/induction therapy, by country, 2016
Figure 26: Proportion of bulky stage mantle cell lymphoma patients receiving less aggressive first-line/induction therapy, by country, 2016
Figure 27: Proportion of bulky stage mantle cell lymphoma patients receiving first-line maintenance therapy, by country, 2016
Figure 28: Trends in incident cases of NHL in the US, Japan, and five major EU markets, 2017-37
Figure 29: Trends in incident cases of DLBCL in the US, Japan, and five major EU markets, 2017-37
Figure 30: Trends in incident cases of FL in the US, Japan, and five major EU markets, 2017-37
Figure 31: Trends in incident cases of MCL in the US, Japan, and five major EU markets, 2017-37
Figure 32: Imbruvica for mantle cell lymphoma - SWOT analysis
Figure 33: Drug assessment summary of Imbruvica in mantle cell lymphoma
Figure 34: Drug assessment summary of Imbruvica in mantle cell lymphoma
Figure 35: Revlimid for mantle cell lymphoma - SWOT analysis
Figure 36: Drug assessment summary of Revlimid in mantle cell lymphoma
Figure 37: Drug assessment summary of Revlimid in mantle cell lymphoma
Figure 38: Rituxan for mantle cell lymphoma - SWOT analysis
Figure 39: Drug assessment summary of Rituxan in mantle cell lymphoma
Figure 40: Drug assessment summary of Rituxan in mantle cell lymphoma
Figure 41: Torisel for mantle cell lymphoma - SWOT analysis
Figure 42: Drug assessment summary of Torisel in mantle cell lymphoma
Figure 43: Drug assessment summary of Torisel in mantle cell lymphoma
Figure 44: Treanda for mantle cell lymphoma - SWOT analysis
Figure 45: Drug assessment summary of Treanda in mantle cell lymphoma
Figure 46: Drug assessment summary of Treanda in mantle cell lymphoma
Figure 47: Velcade for mantle cell lymphoma - SWOT analysis
Figure 48: Drug assessment summary of Velcade in mantle cell lymphoma
Figure 49: Drug assessment summary of Velcade in mantle cell lymphoma
Figure 50: Darzalex for mantle cell lymphoma - SWOT analysis
Figure 51: Gazyva for mantle cell lymphoma - SWOT analysis
Figure 52: KTE-C19 for mantle cell lymphoma - SWOT analysis
Figure 53: Kyprolis for mantle cell lymphoma - SWOT analysis
List of Tables
Table 1: Mantle cell lymphoma market value across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 2: Mantle cell lymphoma market value in the US, Japan, and five major EU markets, by drug status ($m), 2016-25
Table 3: Mantle cell lymphoma drug sales in the US, Japan, and five major EU markets, by drug, 2016-25
Table 4: Revlimid and Velcade sales ($m), 2016
Table 5: Summary of drug classes, molecules, and brands included in the author’s mantle cell lymphoma patient-based forecast
Table 6: Exchange rates used for calculating prices
Table 7: Patent expiry dates for key marketed brands in mantle cell lymphoma, by region
Table 8: Expected label expansion and approval in mantle cell lymphoma, 2016-25
Table 9: Imbruvica sales for mantle cell lymphoma across the US and five major EU markets, by country ($m), 2016-25
Table 10: Imbruvica patient numbers for mantle cell lymphoma across the US, Japan, and five major EU markets, by country, 2016-25
Table 11: Revlimid sales for mantle cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 12: Revlimid patient numbers for mantle cell lymphoma across the US, Japan, and five major EU markets, by country, 2016-25
Table 13: Rituxan sales for mantle cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 14: Rituxan patient numbers for mantle cell lymphoma across the US, Japan, and five major EU markets, by country, 2016-25
Table 15: Torisel sales for mantle cell lymphoma across the five major EU markets, by country ($m), 2016-25
Table 16: Torisel patient numbers for mantle cell lymphoma across the five major EU markets, by country, 2016-25
Table 17: Velcade sales for mantle cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 18: Velcade patient numbers for mantle cell lymphoma across the US, Japan, and five major EU markets, by country, 2016-25
Table 19: Hematologists and hemato-oncologists surveyed for the mantle cell lymphoma primary research study, 2016
Table 20: Hematologists and hemato-oncologists surveyed for the mantle cell lymphoma primary research study, 2016
Table 21: Simplified Mantle Cell Lymphoma International Prognostic Index
Table 22: Ann Arbor classification
Table 23: Targeted drugs for the treatment of mantle cell lymphoma
Table 24: Main cytotoxic therapies for the treatment of mantle cell lymphoma
Table 25: Cancer registry databases used as a source of NHL, DLBCL, FL, and MCL incidence data, by country
Table 26: Ann Arbor classification system
Table 27: Incident cases of NHL in the US, Japan, and five major EU markets, 2017-37
Table 28: Incident cases of DLBCL in the US, Japan, and five major EU markets, 2017-37
Table 29: Incident cases of FL in the US, Japan, and five major EU markets, 2017-37
Table 30: Incident cases of MCL in the US, Japan, and five major EU markets, 2017-37
Table 31: Key marketed drugs for mantle cell lymphoma
Table 32: Imbruvica drug profile
Table 33: Imbruvica pivotal trial data in mantle cell lymphoma
Table 34: Imbruvica late-phase trial data in mantle cell lymphoma
Table 35: Imbruvica ongoing late-phase clinical trials in mantle cell lymphoma
Table 36: Revlimid drug profile
Table 37: Revlimid pivotal trial data in mantle cell lymphoma
Table 38: Revlimid other trial data in mantle cell lymphoma
Table 39: Revlimid ongoing clinical trials in mantle cell lymphoma
Table 40: Rituxan drug profile
Table 41: Rituxan pivotal trial data in B-cell non-Hodgkin’s lymphoma
Table 42: Rituxan clinical studies in mantle cell lymphoma
Table 43: Torisel drug profile
Table 44: Torisel pivotal trial data in mantle cell lymphoma
Table 45: Treanda drug profile
Table 46: Treanda pivotal trial data in mantle cell lymphoma
Table 47: Velcade drug profile
Table 48: Velcade pivotal trial data in mantle cell lymphoma
Table 49: Phase I/II pipeline products in development for mantle cell lymphoma
Table 50: Darzalex drug profile
Table 51: Darzalex Phase II trial in mantle cell lymphoma
Table 52: Gazyva drug profile
Table 53: Gazyva Phase I/II data in mantle cell lymphoma
Table 54: Gazyva Phase Ib/II trial in mantle cell lymphoma
Table 55: KTE-C19 drug profile
Table 56: KTE-C19 Phase I/II trials in mantle cell lymphoma
Table 57: Kyprolis drug profile
Table 58: Kyprolis Phase I/II trials in mantle cell lymphoma
